Modulari-T Biosciences Analysis: $500K Raised
What is Modulari-T Biosciences?
Modulari-T builds proprietary immune engineering platforms for cell therapy and in vivo delivery. Its MARC system separates targeting from signaling, while MoVe is a rationally designed vector for selective delivery. The company says its lead oncology asset targets uPAR and enters IND-enabling studies in 4Q 2026.
Location
6750 Rue Hutchison suite 206, Montreal, Quebec H3N 1Y4, Canada
Employees
1-10
Founded
2021
Product Features & Capabilities
- MARC technology, modular receptors, persistent immune response, complex and logic gated signaling, compatibility across immune cells, compatibility with iPSC/stem cells, scalable and cost-effective.
How much Modulari-T Biosciences raised
1: - $500,000
April 3, 2023Lead Investor: Y Combinator, Pioneer Fund, Metaplanet
Who are the founders of Modulari-T Biosciences
DW
David White
CEO
SM
Market Focus
Modulari-T Biosciences primarily focuses on the biotechnology industry, specifically in the development of cell therapies for cancer and autoimmune diseases.
Business Model
Focus on partnerships and funding rounds for revenue generation and growth strategy.
Investors
- Y Combinator
- Metaplanet
- Pioneer Fund
- Creative Destruction Lab
- MassBio
Competitors Overview
Modulari-T Biosciences operates in the biotechnology sector, focusing on developing modular receptors for next-generation cell therapies aimed at treating cancer and autoimmune diseases. Its main competitors include:
-
Argobio: A French company founded in 2021, Argobio focuses on creating multiple biotech companies targeting rare diseases and oncology. Its advantage lies in sourcing innovative projects from prestigious academic institutions.
-
858 Therapeutics: Established in 2019 in the USA, this company develops small molecule drugs for novel therapeutic areas in oncology. Its team has a strong background in drug discovery, particularly in epigenetics and innate immunity.
-
Normunity, Inc: Founded in 2021, this US-based company is developing a new class of immuno-oncology medicines that target mechanisms disrupting the immune response to cancer. Its collaboration with Yale School of Medicine provides significant academic backing.
-
CureLab Oncology, Inc.: Operating since 2000, this US company focuses on biologics for cancer treatment, with a lead product that enhances the immune response against tumors. Its long-standing presence in the market may provide it with a competitive edge.
-
OnCusp Therapeutics: Founded in 2021, this company specializes in oncology therapeutics and focuses on developing preclinical assets to clinical proof of concept, potentially streamlining its path to commercialization.
These competitors differ in their specific therapeutic focuses, development strategies, and partnerships, which may provide them with unique advantages in the biotechnology landscape.
See something that needs updating? Suggest edits to this profile.